The extent of heart rate reduction during hospitalization using beta-blockers, not the achieved heart rate itself at discharge, predicts the clinical outcome in patients with acute heart failure syndromes  by Takahama, Hiroyuki et al.
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Aim:  It has  been  uncertain  whether  patients  with  acute  heart  failure  syndromes  (AHFSs)  beneﬁt  from  a
lower  heart  rate (HR)  itself  or  from  treatment  for  heart  failure  (HF)  that  reduces  sympathetic  tone  with
consequent  HR  reduction  (HRR).  The  present  study  investigated  the  inﬂuence  of  HRR  during  hospitaliza-
tion  on  the  prognosis  of AHFS  patients.
Methods  and  results:  In 421  AHFS  patients,  we  analyzed  the relationship  between  HRR  during  hospitaliza-
tion  and  the prognosis  after  discharge.  During  a mean  follow-up  period  of  1.9  years,  76 and  55  patients
died  or  were  re-hospitalized  for HF,  respectively.  Although  HR  at discharge  did  not  inﬂuence  cardiac
events  (hazard  ratio  [HR]:  1.00  [95%  CI; 0.99–1.02],  p =  0.22),  the  extent  of  HRR  was  a  predictor  of  cardiac
events  (HR:  0.89  [0.84–0.96],  p <  0.001).  Kaplan–Meier  analysis  revealed  that  the  cardiac  event  rate  of  the
HRR-positive  group  (≥27  bpm  reduction  of  HR  from  114  ± 24 at admission  to 65  ±  11 bpm  at  discharge)
was  signiﬁcantly  lower  than  that  of  the  HRR-negative  group  (≤26  bpm  (=median  value)  reduction  of  HR
from 74  ±  14  to  71  ±  14 bpm).  In  the  HRR-positive  group,  the  cardiac  event  rate  was  signiﬁcantly  lower
in  patients  receiving  beta-blockers.  Furthermore,  the  extent  of HR  change  was  an  important  predictor
of  cardiac  events  among  other  markers,  compared  with  the  change  in  systolic  blood  pressure  or  B-type
natriuretic  peptide.
Conclusion:  The  HR  itself  at discharge  was  not  associated  with  the  prognosis,  but the  extent  of  HRR
achieved  by treatment  of HF with  beta-blockers  was  a  strong  predictor  for  the  clinical  outcome  in  AHFS
patients.
©  2012  Published  by  Elsevier  Ltd on behalf  of  Japanese  College  of  Cardiology.ntroduction
Heart failure (HF) is one of the major causes of morbidity and
ortality worldwide, despite recent remarkable advances in its
reatment [1].  The resting heart rate (HR) has been reported to
e a strong predictor of cardiovascular mortality and morbidity
n patients with chronic HF, hinting at the beneﬁcial effects of
owering the HR [2–4]. It was recently reported that ivabradine,
hich slows HR by selective If current inhibition independently
f the effect of beta-adrenergic receptor blockade, improved the
∗ Corresponding author. Tel.: +81 6 6833 5012; fax: +81 6 6836 1120.
E-mail address: takahama@hsp.ncvc.go.jp (H. Takahama).
914-5087/$ – see front matter © 2012 Published by Elsevier Ltd on behalf of Japanese Co
ttp://dx.doi.org/10.1016/j.jjcc.2012.08.014outcome of HF patients in the Systolic Heart Failure treatment with
the If inhibitor ivabradine Trial (SHIFT) [5].  In contrast, activation of
sympathetic tone has been found to have an important role in the
progression of HF by numerous studies [6,7]. Thus beta-blockers
are used widely in the treatment of HR to reduce cardiovascular
sympathetic tone, which leads to secondary heart rate reduc-
tion [8,9]. However, it has been unclear whether the beneﬁt for
patients with HF is related to lower HR itself or to the inhibition of
sympathetic tone with HR reduction (HRR) as a secondary effect.
Against this background, we  investigated whether the HR itself
at discharge or the extent of HRR was related to long-term mortality
in patients with acute heart failure syndromes (AHFSs). We  also
investigated the differing effects of HRR on long-term mortality in
AHFS patients with or without beta-blocker therapy. In addition,
although previous reports have focused on the inﬂuence of HR in
llege of Cardiology.
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Table 1
Characteristics of the patients.
n 421
Age (y.o.) 72 ± 13
Gender (male %) 281 (67%)
NYHA III 241 (57%)
NYHA IV 169 (40%)
Etiology
Ischemic heart disease 32%
Cardiomyopathy 19%
Hypertensive heart disease 14%
Valvular heart disease 31%
n, number of patients; NYHA, New York Heart Association functional class; y.o., years
for worsening of HF.
Table 2
Characteristics of the patients at admission and discharge.
Admission Discharge
NYHA III 241 (53%) 32 (6%)
NYHA IV 169 (37%) 0 (0%)
SBP (mmHg) 144 ± 37 116 ± 15
HR (bpm) 98 ± 29 68 ± 12
Sinus rhythm % 251 (55%) 276 (61%)
BNP (pg/ml) 959 ± 1073 366 ± 535
Log BNP 2.8 ± 0.4 2.3 ± 0.5H. Takahama et al. / Journa
atients with chronic HF, we investigated the clinical signiﬁcance
f HRR from acute to chronic phase of AHFS.
ethods
tudy design
From July 2006 to June 2009, 545 consecutive AHFS patients
ho met  the Framingham criteria [10] were prospectively enrolled
o National CardiovAScular Center Acute DEcompensated Heart
ailure (nCASCADE) database, which is a single-center registry for
atients with AHFS that excludes patients with acute coronary syn-
romes (ACSs). On admission, the information related to HF was
btained, such as a history of hypertension, dyslipidemia, diabetes,
mplantable pacemaker, dialysis, or chronic respiratory disease.
hysical examination was performed at admission to assess the
ollowing: New York Heart Association (NYHA) functional class,
bsence or presence of congestion (assessed by orthopnea, rales,
ugular venous dilation, abdominal jugular reﬂux, hepatomegaly,
nd edema), adequacy of perfusion [assessed by the proportional
ulse pressure (low < 25%)], cold extremities, and systolic and dia-
tolic blood pressures (BPs), and HR, and the presence of alternans.
R at admission was measured by electrocardiogram (ECG). HR
t discharge was measured at rest by a nurse on the day of dis-
harge. Echocardiography was also done at admission and before
ischarge. Biochemistry tests were performed at admission and
efore discharge, including measurement of blood urea nitrogen,
erum creatinine, hemoglobin, C-reactive protein, total bilirubin,
nd plasma B-type natriuretic peptide (BNP). Patients’ identify-
ng information was not used in the collection of data. This study
as approved by the institutional review board, and was con-
ucted in accordance with the ethical principles of the Declaration
f Helsinki.
xclusion criteria
In the present study, we excluded patients with pacemakers
nd patients who died during hospitalization. We  also excluded
atients with sustained ventricular tachycardia or ﬁbrillation at the
easurement of HR.
linical outcomes
During the follow-up period, we investigated deaths from any
ause and re-hospitalization for HF by telephone and letters. Car-
iac events were deﬁned as all-cause death and re-hospitalization
or HF.
riteria for HRR
Previous studies reported that the mean HRR from admission to
ischarge was  11–29 bpm, although there has been some variation
2,11,12]. In the present study, the HRR was deﬁned as showing a
ecrease of HR ≥ 27 bpm at discharge compared with that at admis-
ion according to a median value of HRR (26 bpm).
tatistical analysis
Results are presented as the mean ± standard deviation (SD).
ultivariate analysis was performed with the Cox proportional
azards model to identify the factors signiﬁcantly related to cardiac
vents after adjustment for other variables. For the multivariate
odel, we included general variables (age, gender, and NYHA func-
ional class) and systolic BP, HR, the presence of sinus rhythm,
og plasma BNP, and left ventricular diastolic diameter (LVDd). For
nvestigation of survival and hospitalization for HF, Kaplan–Meierold.
analysis and the log-rank test were used. Probability (p) val-
ues < 0.05 were considered statistically signiﬁcant. As previously
reported [13], time-dependent ROC curve analysis was  applied to
changing variables (HR, systolic BP, and BNP) with adjustment for
age. This method deﬁned the sensitivity and the speciﬁcity at each
event time as components of the receiver operating characteristic
(ROC) curve. The area under the curve (AUC) indicates the predic-
tive power of each variable. Summary measurements of AUC curves
over time were determined by the integrated summary C index. All
statistical analyses were performed using SPSS software, Version
11 (SPSS Japan, Tokyo, Japan) and SAS version 9.1 (SAS Institute
Inc., Cary, NC, USA).
Results
Characteristics of the patients
According to the exclusion criteria, we  excluded 124 patients
(71 patients with pacemakers, 20 who died during hospitalization,
and 33 whom we  could not follow up because of missing labo-
ratory or any other physical data at the point of discharge) from
the present study. We  excluded patients with sustained ventricular
tachycardia or ﬁbrillation at the measurement of HR. Therefore we
analyzed 421 patients in the present study and their characteristics
are shown in Table 1. There were 281 men and 140 women. Among
the total study population, 241 patients (57%) were in NYHA func-
tional class 3 and 169 (40%) were in NYHA class 4. The causes of HF
were due to ischemic heart disease (32%), cardiomyopathy (19%),
hypertensive heart disease (14%) and valvular heart disease (31%)
(Table 1). The characteristics of these patients at admission and dis-
charge are shown in Table 2. During follow-up for 705 ± 400 days,
76 patients died of any cause and 55 patients were re-hospitalizedLVDd (mm)  55 ± 11 55 ± 11
NYHA, New York Heart Association functional class; SBP, systolic blood pressure;
HR, heart rate; BNP, B-type natriuretic peptide; LVDd, left ventricular end-diastolic
diameter.
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Table  3
Results of univariate and multivariate analyses of risk factors for cardiac events.
Variable Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
Age 1.04 (1.02–1.06) <0.01 1.02 (0.99–1.04) 0.16
Gender 1.10 (0.77–1.56) 0.61 1.09 (0.68–1.73) 0.72
NYHA 1.33 (1.15–1.54) <0.01 1.36 (1.13–1.63) <0.01
SBP 1.00 (0.98–1.01) 0.99 1.00 (0.98–1.01) 0.68
HR 1.00 (0.99–1.02) 0.22 0.90 (0.98–1.02) 0.9
Log  BNP 2.62 (1.71–4.03) <0.01 2.36 (1.35–4.14) <0.01
Creatinine 1.12 (1.00–1.28) 0.04 1.10 (0.86–1.42) 0.44
Atrial  ﬁbrillation 1.11 (0.78–1.57) 0.57 1.02 (0.65–1.61) 0.92
LVDd  1.00 (0.98–1.01) 0.84 1.00 (0.97–1.02) 0.74
%FS 0.90 (0.98–1.01) 0.90 1.00 (0.98–1.04) 0.43
N , heart rate; BNP, B-type natriuretic peptide; LVDd, left ventricular end-diastolic diameter;
%
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Table 4
Comparison of characteristics of the patients between HRR-positive and negative
group.
HRR-negative group HRR-positive group p value
n 208 213
Age (y.o.) 73 ± 12 71 ± 4 0.330
Gender (male %) 59% 69% 0.526
At  admission
NYHA 3.2 ± 0.6 3.4 ± 0.6 0.022
SBP  139 ± 33 148 ± 40 <0.001
HR  77 ± 16 119 ± 23 <0.001
%  Sinus rhythm 63% 55% 0.102
Log  BNP 2.8 ± 0.4 2.8 ± 0.4 0.645
Creatinine 1.3 ± 1.1 1.4 ± 1.4 0.801
Hb 11.3  ± 2.2 12.5 ± 2.3 <0.001
T-Bil 0.8 ± 0.6 1.0 ± 0.8 0.104
LVDd 54 ± 11 55 ± 10 0.034
LVDs 41 ± 13 45 ± 12 <0.001
%FS 25 ± 13 19 ± 10 <0.001
Beta-blockers 43% 36% <0.001
At  discharge
NYHA 2.0 ± 0.8 2.0 ± 0.9 0.942
SBP  117 ± 16 115 ± 14 0.075
HR 70  ± 13 65 ± 11 <0.001
%  Sinus rhythm 63% 67% 0.370
Log  BNP 2.4 ± 0.5 2.3 ± 0.4 0.065
Creatinie 1.4 ± 1 1.4 ± 1.2 0.328
LVDd 55 ± 11 56 ± 11 0.401
LVDs 41 ± 13 43 ± 12 0.104
%FS 27 ± 12 24 ± 11 0.009
Beta-blockers 57% 63% 0.183
ACE  inhbitors 37% 40% 0.483
ARBs 31% 22% 0.035
Digoxin 20% 30% 0.345
Ca  channel blockers 29% 34% 0.018
HRR, heart rate reduction; NYHA, New York Heart Association functional class;
SBP,  systolic blood pressure; HR, heart rate; BNP, B-type natriuretic peptide; LVDd,
left ventricular end-diastolic diameter; LVDs, left ventricular end-systolic diameter;
%FS, % fractional shortening; ACE, angiotensin-converting enzyme; ARB, angiotensin
receptor blocker.
Table 5
Univariate analysis of the inﬂuence of changes of variables during hospitalization.
Variable Univariate analysis
HR (95% CI) p value
SBP/10 0.99 (0.96–1.04) 0.610
HR/10 0.89 (0.84–0.96) <0.001YHA, New York Heart Association functional class; SBP, systolic blood pressure; HR
FS,  % fractional shortening.
ischarge HR
Table 3 shows the results of univariate and multivariate anal-
ses. NYHA functional class and log plasma BNP level were
ecognized as independent predictors of cardiac events in our
atients with HF. However, the HR at discharge was  not related to
he occurrence of cardiac events (hazard ratio [HR]: 1.00 [95% CI;
.99–1.02], p = 0.22). Survival analysis revealed that there was no
igniﬁcant difference in the cardiac event rate between two equal
roups divided according to a median value of HR (=66 bpm) at dis-
harge, which were a lower HR group (≤65 bpm) and a higher HR
roup (≥66 bpm) (Fig. 1A).
hanges during hospitalization for HF
The average HR decreased from 98 ± 29 bpm at admission to
8 ± 12 bpm at discharge (Table 2). According to the HRR criterion,
atients were divided into the HRR-positive group with ≥27 bpm
eduction (from 119 ± 23 bpm at admission to 65 ± 11 bpm at dis-
harge) and the HRR-negative group with ≤26 bpm reduction
from 77 ± 16 bpm to 70 ± 13 bpm). Table 4 compares the char-
cteristics of the HRR-negative and -positive groups. Compared
ith the HRR-negative group, systolic BP was higher (148 ± 40
s. 139 ± 33 mmHg), LVDs was larger (45 ± 12 vs. 41 ± 13 mm),
nd %fractional shortening was lower (19 ± 10% vs. 25 ± 13%) at
dmission in the HRR-positive group. Log BNP was not signiﬁcantly
ifferent between these two groups at admission and discharge.
he ratio of patients receiving beta-blockers at admission was  sig-
iﬁcantly lower in the HRR-positive group than the HRR-negative
roup. In contrast, there was no signiﬁcant difference between the
wo groups at discharge in the respect of the ratio receiving beta-
lockers (Table 4). At discharge, the ratios of patients receiving
ngiotensin receptor blockers and calcium channel blockers were
igniﬁcantly lower and higher in the HRR-positive group than the
RR-negative group, respectively (Table 4). Kaplan–Meier analysis
evealed that cardiac event rate was signiﬁcantly lower in the HRR-
ositive group than the HRR-negative group (p = 0.01) (Fig. 1B).
his tendency was observed in patients with both sinus rhythm
nd atrial ﬁbrillation (Fig. 2A and B). Fig. 3A shows the comparison
f the cardiac events between HRR-positive and -negative groups.
OC curve showed that the extent of HRR was linearly related to
he cardiac events’ AUC (0.607) (Fig. 3B).
Table 5 shows the results of univariate analysis for several
ariables. The changes in both HR and plasma BNP levels were
redictive factors for cardiac events, while systolic BP was  not.
hese ﬁndings were obtained from patients receiving beta-blockers
Table 6A), but not in patients without beta-blockers at discharge
Table 6B). The extent of HRR was signiﬁcantly greater in patients
eceiving beta-blockers (99 ± 30 bpm to 66 ± 12 bpm) compared
%Reduction of BNP 0.99 (0.99–1.00) 0.006
CI, conﬁdence interval; SBP, systolic blood pressure; HR, heart rate; BNP, B-type
natriuretic peptide.
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Fig. 1. Kaplan–Meier analysis of patients with acute heart failure syndromes strat-
iﬁed according to HR. Kaplan–Meier analysis according to the HR at discharge (A)
or  the change of HR during hospitalization (HR; the difference between HR at
admission and discharge) (B). (A) The lower HR group (HR at discharge; ≤65 bpm:
average HR 58 ± 5 bpm, n = 209) and higher HR group (HR at discharge ≥66 bpm:
average HR 76 ± 11 bpm, n = 212) are shown as blue line and red line, respectively.
(B) The HRR-positive group (blue line) showed a reduction of HR by ≥21 bpm at dis-
charge compared with that at admission (n = 213). Average HR at admission and that
at discharge were 119 ± 23 and 65 ± 11 bpm, respectively. The HRR-negative group
(red line) showed a reduction of HR by ≤20 bpm at discharge compared with that
at  admission (n = 208). Average HR at admission and that at discharge were 77 ± 16
and  70 ± 13 bpm, respectively. HR, heart rate; HRR, heart rate reduction. (For inter-
pretation of the references to color in this ﬁgure legend, the reader is referred to the
web  version of the article.)
Table 6A
Univariate analysis in patients treated with beta-blockers (n = 262).
Variable Univariate analysis
HR (95% CI) p value
SBP/10 0.99 (0.95–1.03) 0.519
HR/10 0.86 (0.79–0.94) <0.001
%Reduction of BNP 1.00 (0.99–1.00) 0.264
Table 6B
Univariate analysis in patients treated without beta-blockers (n = 159).
Variable Univariate analysis
HR (95% CI) p valve
SBP/10 0.98 (0.93–1.02) 0.312
HR/10 0.94 (0.85–1.04) 0.236
%Reduction of BNP 1.00 (0.99–1.00) 0.329
CI, conﬁdence interval; SBP, systolic blood pressure; HR, heart rate; BNP, B-type
natriuretic peptide.
Fig. 2. Kaplan–Meier analysis of patients with sinus rhythm or atrial ﬁbrillation
with acute heart failure syndromes stratiﬁed according to HR. Kaplan–Meier analysis
according to the HR in patients with sinus rhythm at admission (A) or with atrial
ﬁbrillation (B). HRR-positive group and -negative group are shown as blue line and
red  line, respectively. HR, heart rate; HRR, heart rate reduction; Pts, patients. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred
to  the web version of the article.)
with those without beta-blockers (95 ± 28 bpm to 70 ± 13 bpm). In
contrast, in the patients without beta-blockers, the HR at discharge
was signiﬁcantly decreased compared with that at admission, but
the extent of HRR was  not signiﬁcantly related to the clinical out-
come by univariate analysis (Table 6B).
Changing variables during hospitalization for HF
When time-dependent ROC was applied to patients with beta-
blockers, the ROC at 1 year showed that the change in HR had
a larger AUC (0.675) than the change in systolic BP (0.635) or
the percent reduction of the plasma BNP level (0.624) (Fig. 2). In
patients without beta-blockers, the change in HR had a smaller
ROC (0.578) than in those with beta-blockers. To determine the
predictive power of the change in HR from admission, we equally
divided the patients with beta-blockers based on the HR at admis-
sion (42–95 bpm and 96–200 bpm) and found that the integrated
AUC indices were 0.68 and 0.60 for the higher and lower HR groups
at admission, respectively, as shown in Fig. 3.
Discussion
In the present study, we found that (1) the achieved HR itself at
the point of discharge does not inﬂuence cardiac events, but (2) the
extent of the decrease in HR from the admission to discharge is a
strong predictor of cardiac events in patients with AHFS with both
sinus rhythm and atrial ﬁbrillation, obviously in patients receiving
beta-blockers, (3) the extent of HR change was an important pre-
dictor of cardiac events among other markers, compared with the
change in systolic BP or BNP during hospitalization for heart failure
(Figs. 4 and 5).
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Fig. 3. (A) Comparison between cardiac events in the HRR-positive and -negative
group. Blue line shows the risk of the cardiac events. (B) Receiver operating charac-
teristic curve between the extent of HRR and cardiac events. Area under the curve for
change of the extent of HRR (HR = HR at admission − HR at discharge) is shown.
HR,  heart rate; HRR, heart rate reduction. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web  version of the article.)
Fig. 4. Time dependent receiver operating characteristic (ROC) curves for changes
of variables at 1 year in patients with or without beta-blockers. Time-dependent
ROC curves at 1 year for changes in HR, systolic BP, and %reduction of plasma BNP in
patients receiving beta-blockers and change in HR in patients without beta-blockers
during hospitalization. They are shown by solid line (upper), dotted line (middle-
upper) and coarse dotted line (lower-upper), ﬁne dotted line (lower), respectively.
BB,  beta-blockers; BNP, B-type natriuretic peptide; BP, blood pressure; HR, heart
rate; Pts, patients.
Fig. 5. AUC of the time-dependent ROC for HR for admission HR. AUC of time-
dependent ROC for change of HR is shown. The upper and lower curves are for
patients with a higher HR at admission (96–200 bpm) and those without a higher HR
(42–95 bpm), respectively. AUC, area under the curve; HR, heart rate; ROC, receiver
operating characteristic.
HRR and HF
Previous studies have shown a relation between HR and the
clinical outcome of HF, and suggested that reduction in HR is ben-
eﬁcial for patients with chronic HF. Several physiological reasons
for this observation can be considered. First, Braunwald reported
that reduction in HR decreases myocardial oxygen consumption
[14], which may  be cardioprotective. Second, the increase in dia-
stolic ﬁlling period with reduction of HR increases coronary ﬂow
and thus prevents subendocardial ischemia in an animal model
[15,16]. Third, beta-blockers are widely used to treat HF, and one of
their effects is reducing the HR in addition to decreasing oxidative
stress and suppression of sympathetic activity in the myocardium
[17–19].
Recently, the SHIFT study revealed a better clinical outcome in
patients with chronic HF receiving ivabradine, which is a selec-
tive If current inhibitor that lowers HR independently of any effect
of blocking of beta-adrenergic receptors [5].  However, it has been
uncertain whether patients with AHFS beneﬁt from a lower HR
itself or from treatment of HF that reduces sympathetic tone with
consequent HRR. In addition, it also remained unknown the signif-
icance of HRR from acute phase during hospitalization for HF and
comparison with other surrogate markers and systolic BP. In the
present study, we addressed these issues as described.
Novel ﬁndings of the present study
In the present study, the extent of the decrease in HR from the
admission to discharge, not the achieved HR at the point of dis-
charge, was a strong predictor of cardiac events in patients with
AHFS compared to other markers during hospitalization, in patients
receiving beta-blockers. To the best of our knowledge, this was
the ﬁrst comparison of HR changes with other markers from acute
phase during hospitalization in patients with AHFS. The extent of
HR change was  found to be an important predictor of cardiac events
among other markers, while that of systolic BP was  not a signiﬁ-
cant predictor in the present study. It has been unclear whether the
extent of change in various parameters during hospitalization for
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F was a predictor of future cardiac events. For example, the plasma
evel of BNP has been conﬁrmed as a diagnostic and prognostic
arker for HF patients [20,21],  but the signiﬁcance of the extent of
hanges in BNP during hospitalization for HF as a predictor of future
vents has been unclear [22,23]. In addition, previous studies have
ocused on the inﬂuence of HR in patients with chronic HF, so the
igniﬁcance of HRR from acute phase in patients with AHFS has
een unclear. We  found the change in HR from admission to dis-
harge was an important predictor of future cardiac events rather
han the absolute HR at discharge.
ossible mechanisms
In the normal myocardium, isometric contraction can be
ncreased by stimulation up to 150–180 bpm [24]. On the other
and, the response of isometric contraction to an increase in
R is depressed in failed myocardium compared with normal
yocardium [24]. It was also reported that reduction in HR
ecreases myocardial oxygen demand and increases the diastolic
erfusion time that is a major determinant of subendocardial blood
ow [14–16]. Indeed, the SHIFT study proved that reduction of
he resting HR is associated with a better clinical outcome for
atients with chronic HF [5].  Consistent with previous studies per-
ormed in patients with chronic HF, we found that HRR from the
cute phase to discharge was a strong predictor for patients with
HFS, while the achieved HR at discharge was not related to the
linical outcome. However, this relation was weaker in patients
ithout beta-blockers in the present study. These ﬁndings sug-
ested that sympathetic inhibition might be also essential when
reating patients with AHFS, synergistic to HRR per se.
To explain the beneﬁcial effects of beta-blockers in the setting
f HF, several pathophysiologic mechanisms have been con-
idered. These include reduced adrenergic drive, a decrease in
atecholamine-induced myocyte apoptosis and ventricular wall
tress, and prevention of beta-receptor downregulation [7–9]. Such
vidence suggested that sympathetic inhibition was  necessary to
ffectively treat patients with HF [25], not only HRR. The ﬁndings of
he present study and accumulating evidence suggest that only HRR
er se might not be sufﬁciently beneﬁcial for patients with acute HF,
n the setting of highly activated systemic sympathetic tone, even
f the HR is slowed by non-beta-blockers such as ivabradine. To
esolve this issue, further investigation and a large-scale random-
zed clinical trial such as the comparison between beta-blockers
nd ivabradine, would be necessary for patients with AHFS.
linical implications
The present study yielded two important ﬁndings with clin-
cal application. First, the extent of decrease in HR was related
o the clinical outcome, in patients with HF who were on beta-
lockers. In other words, the beneﬁt of the HRR was provided to
atients with beta-blockers. Beta-blockers have currently become
 standard therapy for patients with HF. Carvedilol was  reported to
chieve dose-related improvement in patients with chronic HF [26].
n the clinical setting, we usually employ vital signs and surrogate
arkers to decide on up-tiltration of beta-blockers in patients with
F. Although markers such as BNP, BP, and HR have been reported
s useful for adjusting the dose of beta-blockers, it has not been clar-
ﬁed which markers are important for up-titration of beta-blocker
herapy in patients with HF. In the present study, the change in
R was a stronger predictor of cardiac events in patients with HF
ompared with other markers.In addition, both HR and systolic BP at admission in the
RR-positive group were signiﬁcantly higher than those in
he HRR-negative group (119 ± 23 vs. 77 ± 16 bpm, 148 ± 40 vs.
39 ± 33 mmHg, respectively), indicating that the patients withrdiology 61 (2013) 58–64 63
higher HR at admission, whose HR could be decreased using
beta-blockers during the hospitalization for HF, had better clin-
ical outcome than the patients in the HRR-negative group. This
result indicates that our ﬁndings would be mainly applicable to
the patients with higher HR or BP at admission, or in other words,
with highly activated systemic sympathetic tone at admission in
AHFS patients.
Study limitation
There are several limitations in this study. First, it was a single-
center registry with a moderate number of enrolled patients. It was
also an observational study, so it was not designed to compare the
effects of beta-blockers and other treatment slowing HR in patients
with AHFS. Future randomized large-scale clinical trials such as
the comparison between beta-blockers and ivabradine would be
necessary to conﬁrm our ﬁndings.
Second, there was  also a marked difference between HR and
plasma BNP values, so change in BNP value was  analyzed as percent
reduction. Third, we  could not completely exclude the inﬂuence
of ventricular premature conduction. We  could not follow the
change in treatment after discharge in all patients. There is a ten-
dency that patients without beta-blockers were complicated with
valvular regurgitation or bronchical asthma or other complications,
although baseline conditions were similar between the two groups
as shown in Table 4. Since the present study was an observational
study, we  could not set the criteria for beta-blocker administra-
tion. In addition, we  could not evaluate the thyroid function in all
patients at acute phase and completely exclude the presence of
hypo- or hyperthyroidism patients.
Conclusion
The HR at discharge did not predict the risk of future cardiac
events in the present study. In contrast, the change in HR during
hospitalization was a stronger predictor of the risk of future car-
diac events in patients with AHFS compared with other markers, in
patients receiving beta-blockers.
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